Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824704 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
A Phase 2 study, sponsored by pharmaand.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03824704 is a Phase 2 study that was terminated before completion, run by pharmaand. The registered enrollment target is 1 participants.
The verdict
NCT03824704, a Phase 2 study, was terminated before completion, sponsored by pharmaand.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: * Cohort A1: No BRCA mutation in tumor; high level of LOH (loss of heterozygosity) * Cohort A2: BRCA mutation in tumor
Interventions
- DRUG Nivolumab
- DRUG Rucaparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-23 |
| Est. Completion | 2020-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03824704
The ClinicalTrials.gov registry entry for NCT03824704 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is pharmaand, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03824704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03824704 about?
NCT03824704 is a clinical study titled "A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)". This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer. Patients entering the following cohorts must have BRCA mutational status confirmed by a central lab: * Cohort A1: No BRCA mut...
What is the current status of trial NCT03824704?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-08-23. Estimated completion is 2020-08-24.
What interventions are being tested in trial NCT03824704?
The interventions under investigation include: Nivolumab (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03824704?
This trial is sponsored by pharmaand, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.